1. Home
  2. DORM vs ACAD Comparison

DORM vs ACAD Comparison

Compare DORM & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dorman Products Inc.

DORM

Dorman Products Inc.

HOLD

Current Price

$120.42

Market Cap

3.8B

ML Signal

HOLD

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$26.40

Market Cap

4.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DORM
ACAD
Founded
1978
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Auto Parts:O.E.M.
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.8B
4.3B
IPO Year
1996
2000

Fundamental Metrics

Financial Performance
Metric
DORM
ACAD
Price
$120.42
$26.40
Analyst Decision
Strong Buy
Buy
Analyst Count
8
22
Target Price
$160.25
$30.55
AVG Volume (30 Days)
132.0K
1.2M
Earning Date
05-04-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
8.14
69.12
EPS
4.35
0.20
Revenue
$2,130,319,000.00
$726,437,000.00
Revenue This Year
$9.70
$18.80
Revenue Next Year
$4.92
$11.70
P/E Ratio
$28.22
$136.20
Revenue Growth
6.03
40.45
52 Week Low
$98.45
$19.69
52 Week High
$164.00
$30.96

Technical Indicators

Market Signals
Indicator
DORM
ACAD
Relative Strength Index (RSI) 31.48 38.15
Support Level $110.56 $25.00
Resistance Level $130.27 $27.80
Average True Range (ATR) 3.21 0.75
MACD -0.51 -0.25
Stochastic Oscillator 9.59 1.86

Price Performance

Historical Comparison
DORM
ACAD

About DORM Dorman Products Inc.

Dorman Products Inc is a supplier of original equipment parts for automobiles. It offers automotive and heavy-duty replacement parts, automotive hardware, brake parts, and fasteners for the automotive and heavy-duty aftermarket. The products are sold under the Dorman brand and its sub-brands OE Solutions, Help!, Conduct-Tite, Super ATV, etc., through aftermarket retailers, warehouse distributors, specialty markets, and salvage yards. The company operates through three business segments, which include Light Duty, Heavy Duty, and Specialty Vehicle. A majority of its revenue is generated from the Light Duty segment, which designs and markets replacement parts and fasteners mainly for passenger cars and light trucks. Geographically, it derives key revenue from the United States.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Share on Social Networks: